Keros Therapeutics (KROS) announced that the global development and commercialization license agreement with Takeda (TAK) to advance elritercept became effective on January 16, 2025. The agreement, which was previously announced on December 3, 2024, became effective upon the expiration or termination of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended. In connection with the effectiveness of the agreement, Takeda will make an upfront payment to the Company of $200.0 million.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Biotech Alert: Searches spiking for these stocks today
- Keros Therapeutics downgraded at Wedbush after removing PAH, obesity programs
- Keros Therapeutics downgraded to Neutral from Outperform at Wedbush
- Keros Therapeutics price target lowered to $15 from $40 at Piper Sandler